Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute  by Laroia, S.T. et al.
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Objective:  To  investigate  dual-energy  spectral  CT  in  characterization  of  hepatocellular  Carcinoma  (HCC)
in patients  with  chronic  liver  disease.
Methods:  Dynamic  computed  tomography  (CT)  was  performed  in  3600 patients  (2879  males;  721 females,
mean age  50.9  ± 11.9 years)  with  working  clinical  diagnosis  of liver  cirrhosis  for hepatocellular  carcinoma
screening  and  other  clinical  indications.  The  study  was  conducted  over  a period  of  3  years.  During  dynamic
CT scanning,  spectral  (monochromatic)  and  routine  (polychromatic)  CT acquisitions  were  obtained  on  a
single tube,  dual  energy,  64  slice  multi-detector  CT scanner.  Imaging  ﬁndings  were  studied  on routine  CT.
On the  basis  of routine  CT  ﬁndings,  indeterminate  lesions  (lesions  not  showing  characteristic  hypervas-
cularity  followed  by washout  on  dynamic  routine  CT  scan)  that  were  referred  for  biopsy  or  surgery  were
segregated.  A  retrospective  blinded  review  of the lesions,  acquired  by the  spectral  CT acquisitions  was
done  with  the  help  of gem  stone  imaging  (GSI)  software  to characterize  these  lesions.  All  the  above  lesions
were  analyzed  qualitatively  in  the  arterial  phase  for lesion  conspicuity  as well  as  quantitatively  using  the
monochromatic  data  sets and  nodule  Iodine  concentration  on  material  density  maps,  respectively.  This
data  was  studied  with  respect  to predictability  of HCC  using  the  spectral  CT technique.  Iodine  density  of
the  lesion,  surrounding  liver  parenchyma,  and  lesion  to  liver  parenchyma  ratio  (LLR)  were  derived  and
statistically analyzed.  Histopathology  of  the  lesion  in  question  was  treated  as gold standard  for  analysis.
Results:  It was  observed  via  statistical  analysis  that  the value  of  iodine  density  of  the  lesion  on  material
density  sets of  ≥29.5  mg/dl,  enabled  a discriminatory  power  of  86.5%,  sensitivity  of 90.5%  with  95%  con-
ﬁdence  Interval  (CI)  (69.2–98.8%)  and  speciﬁcity  of 81.2%  with  95%  Conﬁdence  Interval  (54.4–95.9%)  in
predicting  HCC.  Qualitative  assessment  also  showed  higher  lesion  conspicuity  with  spectral  CT  image
sets  as compared  to  routine  CT  data.
Conclusion:  This  study  reveals  that spectral  imaging  is an  excellent  qualitative  as  well as  a  quantitative
tool  for  assessing  and predicting  hepatocellular  carcinoma  in  cirrhotic  patients.Abbreviations: HCC, hepatocellular carcinoma; CT, computed tomography; GSI,
em  stone imaging; DECT, dual energy computed tomography; LLR, lesion to liver
arenchyma ratio; MMD,  monochromatic material density; CI, conﬁdence interval.
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1. Introduction
The primary objective of our study was  to determine whether
spectral CT technique can improve accuracy in diagnosis of HCC
in cirrhotic patients. This analysis was  performed to evaluate both
qualitative (lesion conspicuity) and quantitative (using material
iodine density values) aspects of spectral CT respectively. Sec-
ondary end points and objectives of this study were to:
1. Explore spectral CT as a functional tool in patients with HCC.
al of Radiology Open 3 (2016) 162–171 163
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Table 1
Work ﬂow-chart of study design and method of conducting the study.S.T. Laroia et al. / European Journ
. Assess the accuracy and reliability of a new assessment parame-
ter of measuring iodine density of enhancing liver nodules on the
arterial phase of CT instead of the traditional quantiﬁcation done
by calculating their attenuation values in Hounsﬁeld units.
. Assign a range of iodine density values to conﬁrmed HCC nodules
so as to be able to form an objective, quantitative, value-based
classiﬁcation for liver cancer nodules on a future long term basis.
The revised European association of study of liver diseases
EASL) and American association of study of liver diseases (AASLD)
ractice guidelines on the diagnosis and management of HCC,
iven in 2012 and 2010 respectively, changed the way; imag-
ng is being performed for surveillance and detection of liver
esions in patients with chronic liver disease. [1] AASLD guide-
ines recommend abdominal ultrasonography every 6 months for
urveillance of ‘at risk’ population of active chronic hepatitis B, cir-
hotic patients and patients in the 40–50 years bracket. [1] The
ASL guidelines recommend patients with chronic hepatitis C infec-
ion and advanced stage of F3 liver ﬁbrosis, regardless of cirrhosis,
o undergo surveillance with ultrasonography. [2] The practical
pproach to reliability of ultrasonography to detect small lesions
< 1 cm)  in a diffusely nodular liver appears questionable. For this
eason, dynamic, contrast enhanced, CT is recommended to further
etect and characterize such lesions. [3,4] The standard algorithm
or diagnosis of HCC is the demonstration of the phenomenon of
ypervascularity of a nodule or lesion in the arterial phase with
ubsequent hypoattenuation or “wash-out” of the lesion compared
o rest of the normally enhancing liver parenchyma on the por-
al venous or equilibrium phase. [3–5] The challenge however; is
o characterize nodules, which do not show adequate hypervascu-
arity on the arterial phase or demonstrate inadequate “wash-out”
n later phases of routine dynamic CT or MRI. These lesions are
haracterized as ‘indeterminate’ nodules on imaging and require
iopsy with histopathology or further investigations (e.g. contrast
nhanced sonography with kupffer cell speciﬁc contrast/MRI with
PIO or hepatocyte speciﬁc contrast) which may  or may  not be
vailable at all centers. MRI  is universally recognized as a problem
olving modality and has a higher procedure cost with worldwide
imited availability. These indeterminate/atypical tumors may  be
ifﬁcult to diagnose, even with all the above criteria put together.
iopsy is the current gold standard of diagnosis however; smaller
esions are technically difﬁcult to visualize and may  show lack of
ufﬁcient tissue, with nodule heterogeneity within the lesion itself.
he ﬁne needle aspiration or biopsy sample may  not be representa-
ive of the entire nodule. To overcome the above lacunae, we  have
ried to explore spectral CT for its diagnostic capabilities in context
o diagnosis of HCC, in patients with pre existing chronic liver dis-
ase, regardless of the underlying etiology. The advent of spectral
T is based on the principle that this technique involves scanning
t distinctly different energies (most commonly used energy levels
re 70 and 140 kVp) using a setup of single or dual x-ray tubes with
etectors operated at two distinct energies or rapidly switching
etween two  different energies depending on the manufacturer.
6–9] This is based on the physics principle of ‘Photoelectric effect’
hich, is used to obtain additional information regarding tissue
omposition. The photoelectric effect essentially utilizes the dif-
erence in the K-edges of two elements. This principle works best
or post contrast CT scans due to the use of Iodine, which has a K-
dge of (33.2 keV). This K-edge is closer to lower energies (80 kVp)
ompared with higher energies (140 kVp) on a spectral (essentially
 dual energy) CT scan and hence Iodine containing tissue is more
ttenuating (better visualized) at lower energies. The higher atten-
ation of Iodine results in improved conspicuity of hypervascular
Iodine rich) nodules in contrast to rest of the liver parenchyma.
We  have tried to ascertain a baseline value of iodine material
ensity in the arterial phase of histopathological proven cases ofAbbreviations: HU—Hounsﬁeld Units; HAP—Hepatic arterial Phase; LLR—Lesion to
liver parenchyma iodine density ratio.
HCC which were labeled as “indeterminate” nodules on routine
dynamic imaging. This is based on the hypothesis that we may  be
able to deﬁne a possible cut-off value at which we can predict the
diagnosis of HCC using spectral CT alone. Our long term goal is to
explore spectral CT as a functional tool using iodine density as a
predictor of tissue composition and tumor grading. In future, this
may  obviate the need for biopsy, completely. We  may  be able to
characterize HCC on a single-phase study, reducing radiation expo-
sure, dosage of intravenous contrast as well as the need for second
modality conﬁrmation.
2. Material and methods
A total of 3600 patients (mean age 50.9 ± 11.9 years, 2879 males
and 721females), who  were clinically proven to have liver cirrhosis
due to various etiologies were scanned by routine CT (with simul-
taneous acquisition of spectral CT data sets) over a period of three
years at our tertiary liver care hospital. All patients with liver cir-
rhosis, who  had indeterminate liver nodules on dynamic routine
CT (irrespective of the lesion size) and were, advised a histopatho-
logical analysis on imaging were enrolled in the study group. This
comprised our study group of 37 patients (mean age 51.65 ± 12.33
years, 33 males and 4 females) who underwent further histopatho-
logical assessment or surgical excision of these lesions. A blinded;
retrospective, double reader, single centered analysis of the spec-
tral CT data was  conducted in a clinical framework. The workﬂow
of the study is demonstrated in a ﬂow chart given below. (Table 1).
2.1. Inclusion criteria‘Indeterminate nodule’ was deﬁned as uncharacteristic/atypical
enhancement pattern of HCC, not conforming to classical arterial
hypervascularity and portal venous or equilibrium phase washout
on dynamic scans.
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.2. Exclusion criteria
Patients who did not have background liver cirrhosis, patients
ho did not consent to evaluation with biopsy and histopathology
nd pregnant and lactating women. Patients in whom no possibility
f imaging diagnosis of HCC was present on routine CT were also
xcluded from this study group. The institutional ethical committee
aived off permission for retrospective analysis of data. Strict con-
dentiality was maintained and voluntary informed consent was
aken before participation.
.3. Spectral CT scanning technique
Routine dynamic CT was performed on a single tube, multi-
etector (64 slice) spectral scanner with fast kVp switching
echnology (GE Healthcare, USA) scanner. All patients were scanned
ranio-caudally, in the supine position using injectable nonionic
ontrast material (Iomeprol, 400 mg/dl Iodine, calculated as 1.5 ml
er kilogram of body weight) at the rate of 4 ml/s pumped through a
ressure injector. A saline bolus of 50 ml  was given at the same ﬂow
ate after the contrast injection. Scan delay for dynamic phase was
etermined by using automated scan triggering software (Smart
rep; GE Healthcare). Scanning was simultaneously performed
n the spectral imaging mode with fast tube voltage switching
etween 80 and 140 kVp on adjacent views during a single rotation.
ther scanning parameters were as follows: collimation thickness
f 0.625 mm,  tube current of 600 mA,  rotation speed of 0.6 s& heli-
al pitch of 0.983. The three sub groups of image data sets which
ere reconstructed from the single spectral acquisition for analy-
is were as follows: a set of polychromatic images or the routine
ynamic CT, corresponding to the conventional 140 kVp imaging
which was studied previously and used for segregating our patient
tudy group as indeterminate lesions for a blind review through
pectral imaging), monochromatic image sets with photon ener-
ies ranging from 40 to 140 keV(used for qualitative analysis) and
odine-based material-decomposition images (used for quantitative
nalysis). (Fig. 1) The latter two sets of spectral CT acquisitions were
nalyzed with the GSI Viewer software 4.4 (GE Healthcare, Wauke-
ha, Wisconsin), with a standard soft-tissue display window preset
WL  40 and WW 400). The monochromatic image sets were read at
 low keV of 55 keV (which has been found optimal for studying
iver lesions, without minimum image noise and best visualiza-
ion of contrast between lesion and normal parenchyma). [10,11]
or the quantitative analysis of monochromatic sets, two circular
egions-of-interest (ROI) were placed on the lesion and the liver
arenchyma individually. For each ROI the mean number of pix-
ls were 400; range, 310–560 which was placed in the maximum
nhancing portion of the lesion, hepatic parenchyma surrounding
he lesion and the abdominal aorta at the same axial section of the
bdomen, keeping the size, shape, and position of the ROI consis-
ent by applying the copy-and-paste function. The values of the ROI
n HU were then plotted on a spectral HU graph with z axis repre-
enting 40–140 kVp spectrums and the Y axis representing the HU
alues (Fig. 2). This is a graphical representation of lesion conspicu-
ty with respect to the background liver. The attenuation of Aorta
as used to normalize (baseline standard reference) value of the
esion and liver for constructing the spectral curve. (Fig. 2).
The qualitative analysis of lesion visibility and conspicuity was
raded on an ascending scale of 1–5 with Grade 1 indicating
oor visualization of lesion, Grade 2: lesion visualized however
rterial enhancement absent, Grade3: adequate visualization of
esion with mild arterial enhancement, Grade 4: adequate visual-
zation of lesion with moderate arterial enhancement and Grade
 indicative of excellent lesion visualization with bright arterial
nhancement. The sets of monochromatic images described above
nd the Iodine-based material-decomposition datasets were takenadiology Open 3 (2016) 162–171
into consideration. These were independently read by two  radiol-
ogists (YV, STL) with experience in hepatobiliary CT imaging for 5
and 10 years respectively. Qualitative analysis of lesion conspicu-
ity with the same grading system was done on the polychromatic
images acquired from routine CT data and both data were com-
pared using agreement analysis, Interclass correlation (ICC) with
95% conﬁdence intervals and Bland-Altmann graphs.
2.4. Quantitative analysis
The Iodine-based material-decomposition set of images were
used to derive iodine quantiﬁcation (measured in mg/dl) of the
lesion and rest of the liver, in the HAP (Fig. 3). Scatter plots were
drawn after quantifying the iodine content using standard and uni-
form sized ROI’s within the enhancing portion of the lesion, liver
parenchyma and the Aorta (for baseline enhancement and nor-
malization of data). (Fig. 3). These parameters were tabulated and
statistically analyzed. The various calculated parameters were as
follows:
a) On the Material decomposition image sets (Iodine concentration
measured in mg/dl)
) GSI enhancement value (GSI) of Lesion = GSI lesion
c) GSI enhancement value (GSI) of Liver = GSI Liver
) Lesion-to–parenchyma ratio (LLR) = Ratio of Iodine concentra-
tion in lesion/Iodine concentration in liver
e) GSI enhancement value (GSI) of Aorta = GSI Aorta
2.5. Reference standards
The imaging diagnosis was made with the radiologists blinded
to the end result of biopsy and histopathology which were consid-
ered as reference gold standard. The grading system of Edmondson
and Steiner was used as standard for HCC grading protocol by
the pathologist. [12] The investigators were also blinded to the
clinical history and results of serum Alfa feto protein (AFP) level,
which is used as an important screening and surveillance marker
for HCC. The results were used to further sub-divide the patient
groups into true positive HCC (those which were conﬁrmed by ref-
erence gold standard to be same as imaging results of HCC), true
negatives (those which were reported as non malignant by imag-
ing and conﬁrmed to be non malignant on biopsy), false positives
(those which were diagnosed on imaging as HCC but were proven
to be non-malignant on histopathology) and false negatives (those
HCC’s which were missed on Imaging but were conﬁrmed HCC on
histopathology).
2.6. Calculation/statistical analysis
The data is presented as proportions; mean ± standard devia-
tions, median with interquartile range or in frequencies (%). The
statistical methods applied were proportion test and Mann Whit-
ney U test, wherever applicable. Besides this, diagnostic tests were
applied to calculate the various characteristics for diagnosis. Data
were also compared using agreement analysis between the two
readers using Interclass correlation (ICC) with 95% conﬁdence
intervals and Bland-Altmann graphs were plotted.
Receiver operating characteristic curves (ROC) were used to
depict cut off values and calculate the area under curve. Sensitivity,
speciﬁcity, positive predictive values, negative predictive values
were used to diagnose and characterize lesions objectively. P value
less than 0.05 were considered as signiﬁcant.
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Fig. 1. 55 year old male with hepatitis B related chronic liver disease on follow up CT scan with three sets of image datasets for analysis. a. Polychromatic routine dynamic
arterial  phase image to depict faintly enhancing lesion in segment IV of liver (bold arrow). b. Monochromatic image viewed at 55 keV from the spectrum of images derived
between 40 to 140 kVp with lesion conspicuity more than previous routine image (bold arrow). c. Material decomposition image showing Iodine containing structures with
rest  of the components appearing suppressed, the focal lesion (bold arrow) shows iodine enhancement on the Iodine map.
Fig. 2. 55 year old male with hepatitis B related chronic liver disease on follow up CT scan showing axial section of the superior aspect of the liver in the arterial phase with
spectral HU curve of enhancing lesion. a. Axial section of the superior aspect of liver showing ROI’s in the enhancing portion of the liver lesion labeled as (1), the surrounding
liver  parenchyma as (3) and within the aortic lumen as (2). b Spectral HU curve of the same lesion denoting the normalized aorta on the top of the graph (bold vertical arrow),
the  graph of the liver lesion in comparison to the normalized aorta (horizontal arrow without ﬁll) and the normal liver curve (vertical arrow without ﬁll).
Table 2
Histopathology results of Non Hepatocellular lesions found indeterminate on Routine CT.
Non HCC histopathology Number of particular lesions (Of a total of 16) Percentage of the lesion (in%)
Regenerative Nodule 4 25
Hepatocellular −Cholangiocarcinoma (mixed tumor) 3 18.75
Secondaries from unknown occult primary tumor 2 12.5
No  tumor cells, normal hepatocytes (Likely arterio-portal shunts) 3 18.75
Fibrolamelllar Carcinoma 1 6.25
3
a
3
wMesenchymal tumor 
Cholangiocarcinoma 1 
Hemangioendothelioma 1 
. Results
A total of 37 patients (mean age 23.5 ± 10.7 years) 22 males
nd 39 females, were analyzed within the study group. Of these,
7 patients; 21 were diagnosed to have HCC vs 16 patients who
ere found to have non HCC lesions on histopathology (Table 2).6.25
6.25
6.25
Histopathological tumor grading evaluation of HCC lesions showed
that 4/21 (19%) tumors were Grade 3 and 17/21 (81%) lesions
were Grade 2 HCC. Mean age of the HCC vs Non HCC groups was
52.67 ± 12.14 Vs 50.3 ± 12.5 years (p = 0.57), gender distribution:
54.5 males vs 25.6% females (p = 0.77) respectively. The distribu-
tion of lesions in HCC vs non HCC group (p = 0.30) with respect to
166 S.T. Laroia et al. / European Journal of Radiology Open 3 (2016) 162–171
Fig. 3. 45 year old male patient with a cirrhotic liver showing hypervascular lesions. Axial material decomposition images showing iodine density values and scatter plot of
the  lesions. a. Axial iodine density map  of the material decomposition image dataset depicting iodine quantiﬁcation done within the liver lesion using an ROI labeled (1), the
surrounding liver parenchyma labeled as (2) and the Aorta as (3). b The values of the ROI’s measuring Iodine density in mg/ml of the liver lesion (horizontal arrow without
ﬁll)  and the surrounding liver curve (vertical arrow without ﬁll) has been plotted on the scatter plot with values normalized against the density in the Aorta ((bold vertical
arrow).
Table 3
Anatomical CT distribution of various lesions in the segments of liver.
Location of the lesions in segment of liver HCC lesions Non HCC Lesion (n = 21 lesions) Total lesions (n = 16lesions)
Segment 2 3 (14.3%) 1 (6.2%) 4 (10.8%)
Segment 3 3 (14.3%) 0 (0%) 3 (8.1%)
Segment 4 3 (14.3%) 5 (31.2%) 8(21.6%)
Segment 5 2(9.5%0 2(9.5%0 4(10.8%)
3(18.8%) 6 (16.2%)
4(25.0%) 6(16.2%)
1(6.2%) 6(16.2%)
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Fig. 4. Bland and Altmann graph depicting 2 observer agreement analysis on routineSegment 6 3(14.35) 
Segment 7 2(9.5%) 
Segment 8 5(23.8%) 
egment of liver has been depicted in (Table 3). Median lesion size
f HCC vs non HCC groups was found to be 2 (IQR 0–16) vs 4 (IQR
–9) cms, (p = 0.77).
The median grade (qualitative analysis) for visualization of HCC
n routine CT was 2 (IQR 1–4) vs 2.5 (IQR 1–4) for non HCC lesions,
p = 0.59). The median grade for visualization of HCC on spectral CT
as 4 (IQR 3–5) vs 5 (IQR 3–5) for non HCC lesions, (p = 0.30).
The agreement between two observers was seen using Intra
lass correlation (ICC). The ICC for routine CT was found to be 91.6%
ith 95% CI (81–96%). 2.7% cases were not in agreement with the
wo observers. (Fig. 4) Similarly the agreement between the two
bservers on spectral CT was found to be 88.9%, with 95% CI (77–94).
.7% cases were not in agreement with the two observers. (Fig. 5).
The parameters that were considered for quantitative analysis
ere subgroups of iodine density GSI lesion, GSI aorta, GSI liver
nd ratio of GSI lesion to surrounding liver parenchyma (LLR). The
wo groups for summary statistics were divided as per the biopsy
esults into biopsy proven HCC and non HCC as shown in Table 4.
here were total of 37 cases, out of which 21 were HCC and 16
ere non HCC cases on histopathology. On spectral CT, there were
3 (35.1%) true positive and 12 (32.4%) true negatives. The number
f false negative (missed on spectral CT) cases were 8 in number
21.6%) and the false positive cases (incorrectly classiﬁed as HCC on
pectral CT were 4 (10.8%).
The average GSI lesion value for the HCC group was
7.7 ± 29.1 mg/dl and for non HCC group was 23.2 ± 10.8 mg/dl and
howed statistical signiﬁcance (<0.001) between the two groups.
he average value for the GSI iodine density of Aorta in the arte-
ial phase of HCC group was 152.3 ± 24.2 mg/dl. The GSI iodine
ensity of Aorta in the non HCC group was 144.4 ± 26.3 mg/dl.CT  observations of qualitative lesion conspicuity.
The mean GSI density of liver surrounding parenchyma in the
HCC group was 60.6 ± 13.9 mg/dl and in the non HCC group was
62.0 ± 20.4 mg/dl. The ratio of lesion iodine density to the surround-
ing liver parenchyma iodine density (LLR) showed an average value
of 1.2 (0.7–1.4) in the HCC group and 0.3 (0.2–0.6) in the control
group. This was  found to be signiﬁcant (p < 0.001) (calculated using
Mann Whitney U test). These results enabled us to differentiate HCC
from other lesions on spectral CT. We  further analyzed the data to
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Table  4
Comparison of spectral CT parameters between HCC and non HCC groups.
Parameter calculated on spectral CT HCC lesions N = 21 Mean ± SD Non HCC lesions N = 16 Mean ± SD p value (Student ‘t’- test)
GSI lesion (mg/dl) 67.7 ± 29.1 23.2 ± 10.8 <0.001
GSI  Aorta (mg/dl) 152.3 ± 24.2 144.4 ± 26.3 0.802
GSI  liver (mg/dl) 60.6 ± 13.9 62.0 ± 20.4 0.349
GSI  LLR ratioa 1.2 (0.7–1.4) 0.3 (0.2–0.6) <0001#
# Mann-Whitney U test.
a Median with Inter-quartile range.
Table 5
Diagnostic characteristics of spectral CT in HCC.
Parameter Cut off value Area under curve (95% CI) P value Sensitivity Speciﬁcity PPV NPV Correctly classiﬁed
GSI Lesion ≥29.5 0.94 (0.87–1.00) <0.001 90.5 (69.2–98.8) 81.2 (54.4–95.9) 86.4 (65.1–97.1) 86.7 (59.5–98.3) 86.5%
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Cig. 5. Bland and Altmann graph depicting 2 observer agreement analysis on spec-
ral CT observations of qualitative lesion conspicuity.
istinguish the HCC group on the basis of a cut off value. These are
xplained in Table 5 given below.
It has been shown in Table 5 that, if the value of GSI lesion is
29.5 mg/dl of iodine, then the discriminatory power is 86.5% with
 sensitivity of 90.5% CI (69.2–98.8%) and speciﬁcity of 81.2% with
5% CI (54.4–95.9%). (ROC curve, Fig. 6) Hence GSI lesion values can
e used for discriminating the indeterminate cases performed on
pectral CT.
The comparison between biopsy results and spectral CT (GSI
arameters in this case) technique shows that usage of spectral
ual energy CT with objective criteria of material density in the
orm of iodine density of suspected lesions was  able to determine
t-least two more cases which could not be diagnosed on the initial
ualitative assessment of lesions on the spectral HU curve analysis
nd monochromatic images.
. Discussion
Surveillance and screening of HCC is an important factor in
ecreasing the overall cost of its treatment in patients with known
LD as well as in improving the survival of diseased patients. The
im of surveillance is to diagnose a malignant nodule at its earliest
tage, so that the treatment has the highest possible likelihood of
ure with the existing treatment options. Majority (almost 80%) of
CC’s are seen in patients with cirrhosis due to viral infections. [13] prospective controlled study showed that the annual incidence of
CC in hepatitis B carriers was 2.5%. [14,15] The annual incidence
ncreases with age. The risk of HCC in patients with chronic hepatitis
 is highest among patients who have established cirrhosis, whichFig. 6. ROC curve for GSI lesion in HCC group.
is between 2%-8% per year. [16–18] Our study was conducted in an
endemic belt for chronic hepatitis B and C infected patients. Imag-
ing of the cirrhotic liver is a diagnostic challenge for radiologists
when it comes to characterization and differentiation of regenera-
tive, dysplastic nodules as well as early HCC nodules. These nodules
are superimposed on a background of morphologically altered and
chronically diseased liver parenchyma. Regenerative nodules are
essentially normal hepatocyte containing tissue that shows nodular
proliferation in a damaged liver. They have no malignant poten-
tial and are usually isoattenuating to the liver parenchyma but
may  appear hypoattenuating to the liver. MRI  is utilized as the
standard problem solving modality for indeterminate lesions, for
follow up of known malignancies and post radiofrequency ablation
or chemoembolization. However; because of its higher cost and
limited availability at all centers, it is the need of the hour today to
look for alternate options within the existing technology. Although
biopsy is considered as a gold standard for evaluation of indetermi-
nate lesions, it has its own technical issues, in assessing nodules of
small size, lack of sufﬁcient tissue obtained and ill visualization of
the nodule in a cirrhotic liver. Moreover, histopathology of a hetero-
geneous nodule, with variable amounts of hepatocytes, dysplastic
tissue, malignant cells or fat within a single lesion, may  not be rep-
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Fig. 7. 55 year old male with hepatitis B related chronic liver disease on follow up CT scan. Comparison of an enhancing heterogeneous lesion in segment VIII of liver on
routine  versus low keV spectral CT. a. Enhancing component (open arrow) on routine CT. b. The enhancing lesion (bold arrow) is better visualized on low (55) keV spectral
CT  monochromatic image. c. The low attenuation (central ROI within it) showing ﬂuid attenuation of 5HU on the routine CT.
Fig. 8. 55 year old male with hepatitis B related chronic liver disease on follow up CT scan. Spectral HU curve plot and GSI scatter plots to depict the attenuation and iodine
density values of the low density portion of the nodule in segment VIII, seen in Fig. 7c. a. Spectral HU curve depicting the negative attenuation (green tracing on the graph)
suggestive of fat component with the arrow showing the approximate values compared to the lesion (royal blue color trace) and the aorta enhancement (light blue trace).
The  fatty attenuation of the area marked (*). b. GSI scatter plot showing the iodine density of the same three lesions as depicted in Fig. 8a.
S.T. Laroia et al. / European Journal of Radiology Open 3 (2016) 162–171 169
F
s
r
o
t
o
g
k
o
l
z
b
w
m
i
t
t
c
F
C
aig. 9. Gross specimen post hepatectomy showing the nodule (dotted circle) −
teatohepatic variety of HCC) containing fat (*) within it.
esentative of the entire nodule. Similar issues may  be encountered
n imaging such as on routine CT, which may  be unable to differen-
iate the low attenuation of fat area within a steatohepatic variant
f HCC from ﬂuid. We were able to demonstrate fat within a hetero-
eneous lesion with the help of spectral curve values, at low (55)
eV. (Figs. 7–9)
The target of differentiating malignant lesions on imaging can
nly be actualized by using newer and more advanced technology
ike spectral CT scanners. With the help of the above, characteri-
ation of the benign and malignant liver lesions with accuracy is
ound to affect the prognosis and treatment methods in patients
ith liver cirrhosis. Accurate diagnosis and characterization of
alignant nodules, on a background of a diffusely cirrhotic liver,s the responsibility of the radiologist, since clinical suspicion and
umor markers may  not be elevated in all malignant or dysplas-
ic nodules. [19,20] Attenuation difference observed with routine
omputed tomography (CT) has poor sensitivity in characteriza-
ig. 10. 63 year old cirrhotic male patient presented with suspicious blush at the porta, e
T  shows a deﬁnite focal (arrow, black outline) area of blush. b. Spectral HU curve show
rrow pointing at attenuation difference) only at low keV as analyzed (yellow line tracingFig. 11. Gross specimen of the mass (white arrow with black outlines) (moderately
differentiated Grade 2 HCC on histopathology) with bile duct tumor thrombus, small
vessels invasion, embolization and the bile duct, seen separate from mass.
tion of the nature of liver nodules. [21,22] HCC is characterized
on dynamic CT by the classical pattern of arterial hypervascular-
ity and washout on equilibrium phases; however, hypo-vascular
or atypical tumors may  be difﬁcult to diagnose with these crite-
ria. [23,24] Compared to conventional multi-detector CT scanners,
the advanced technique of spectral CT allows differentiation of
material and tissue composition, based on differences in iodine
and water densities [25,26] The use of advanced spectral CT
has revealed that lower (80 kVp) images demonstrate a better
image contrast than higher (140) kVp images which allow rela-
tively hypovascular lesions to be easily visualized on the low keV
monochromatic datasets. [8,15, 27 and 28] An example of this
has been demonstrated in (Fig. 10). This lesion was found to be
relatively hypovascular on routine CT and was virtually indistin-
guishable on it. Application of low keV spectral CT, made the lesion
conspicuous and the spectral HU curve values were able to show
that the lesion was  actually hypervascular compared to the liver
parenchyma. (Fig. 10) Histopathology found HCC invading the bile
duct with tumor thrombus within it. (Fig. 11)
Low keV spectral studies and MMD  images appear to be useful
for the evaluation of enhanced liver lesions in the arterial phase in
valuated on a dynamic CT followed by analysis on spectral CT. a. Low keV (55kev)
s that lesion (open white arrow in iodine density map) is visualized (white curved
 of the lesion).
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CC. In the liver, spectral CT may  be used to increase conspicuity of
ypervascular lesions; to distinguish hyperattenuating cysts from
nhancing focal liver lesions and to characterize masses, hyper-
ascular metastases, as well as to differentiate between normal
ariant areas of hypervascularity such as transient hepatic attenu-
tion defects (THAD) and abnormal parenchyma. [29] An example
f this was demonstrated by a patient from our study group, who
howed a hypervascular mass in the left lobe, with an attending
rea of suspicious blush seen around it, which could not be differen-
iated from the mass itself. On application of spectral CT technique,
e were able to differentiate the area of THAD from the actual
esion, which allowed us to make accurate decisions on treatment
herapy since the lesion size could be adequately assessed with the
elp of the iodine density sets. It has been found on comparison of
0 and 140 kVp images that 80 kVp images with a high mA  enabled
he visualization of a greater number of lesions compared to 140 kVp
mages to detect hypervascular lesions in vitro and in vivo. [28,30]
 range of keV value has been recommended in studies published
n literature to study data sets for the best contrast-to-noise ratio
CNR) between liver lesions and underlying liver parenchyma as
ell as for lesion conspicuity. [7,8] 80 kVp images were also docu-
ented to be superior for the distinction of metastases in normal
iver tissue. [27] Low keV spectral CT and iodine density images are
ble to delineate diffuse inﬁltrative masses which may  be virtually
ndistinguishable on a routine CT, especially since these tumors are
pparently hypovascular on routine CT and hence may  not show
dequate washout.
The functional aspect of spectral CT has been proposed by
emonstrating how increasing arterial vascularity and decreasing
ortal ﬂow to nodules is predictive of transition from borderline
esions to malignant nodules over a period of time. [21,22] This
spect of spectral CT and quantitative analysis of iodine density
ithin a liver nodule, which can predict its vascularity, forms the
asic concept of our study. Similar study models have been utilized
n the mediastinum and chest to differentiate between benign and
alignant lesions within the mediastinum [31,32].
Our study has been able to distinguish approximately 86% of
he lesions which were primarily categorized as indeterminate
odules/masses on routine dynamic CT, to be malignant. This is sig-
iﬁcant in a population which underwent biopsy/invasive surgery
o determine the ﬁnal outcome of the nodules in question.
Our study, had a few limitations such as: sample bias (included
nly cirrhotic patient population), sample size (since number of
atients found suitable for biopsy and surgery is limited in patients
ith HCC) and the need for further comparison within groups of
enign (regenerative, siderotic) and malignant (dysplastic, well dif-
erentiated and poorly differentiated lesions) nodules in patients
ith cirrhosis. All hypervascular masses, besides HCC, which may
resent in a cirrhotic liver, such as hypervascular metastases or
esenchymal tumors of the liver like angiosacroma’s may  be dif-
cult to differentiate till further analysis to compare the various
ub-types of hypervascular tumors is made.
In future, similar studies with larger populations and in-depth
tudy of nodule composition, may  pave the path for reduced biopsy
rocedures. Furthermore, spectral assessment of material compo-
ition may  allow tumor grading without histopathology. We,  for the
rst time, tried to identify HCC from non HCC lesions by quantifying
heir enhancement using iodine density values, on multi spectral
T. To date, there are no studies using spectral CT for this purpose.
he above results show that instead of biopsy we can use the cutoff
oint of iodine density within the lesion on the material density
mages as 29.5 mg/dl to diagnose HCC on spectral CT when routine
T is unable to characterize the nature of these lesions.
[adiology Open 3 (2016) 162–171
5. Conclusions
This study reveals that spectral imaging is an excellent tool for
qualitative as well as quantitative tool for assessing indetermi-
nate lesions in patients with chronic liver disease. It can be used to
create a novel design with material (iodine) density measurements
that will serve as a functional tool to derive the composition of liver
nodules.
References
[1] J. Bruix, M.  Sherman, Management of hepatocellular carcinoma: an update
AASLD, American Association for the Study of Liver Diseases, Hepatology 53
(March (3)) (2011) 1020–1022, http://dx.doi.org/10.1002/hep.24199, PMID:
21374666.
[2]  European Association for the Study of the Liver, European Organisation for
Research and Treatment of Cancer, EASL-EORTC clinical practice guidelines:
management of hepatocellular carcinoma, J. Hepatol. 56 (2012) 908–943.
[3] M.  Omata, L.A. Lesmana, R. Tateishi, P.J. Chen, S.M. Lin, H. Yoshida, et al., Asian
Paciﬁc Association for the Study of the Liver consensus recommendations on
hepatocellular carcinoma, Hepatol. Int. 4 (2010) 439–474.
[4] M.  Kudo, N. Izumi, N. Kokudo, O. Matsui, M.  Sakamoto, O. Nakashima, et al.,
HCC  expert panel of Japan society of hepatology: management of
hepatocellular carcinoma in japan: consensus-based clinical practice
guidelines proposed by the Japan society of hepatology (JSH) 2010 updated
version, Dig. Dis. 29 (2011) 339–364.
[5] A. Forner, R. Vilana, C. Ayuso, L. Bianchi, M.  Solé, J.R. Ayuso, L. Boix, M.  Sala, M.
Varela, J.M. Llovet, C. Brú, J. Bruix, Diagnosis of hepatic nodules 20 mm or
smaller in cirrhosis: prospective validation of the noninvasive diagnostic
criteria for hepatocellular carcinoma, Hepatology 47 (January (1)) (2008)
97–104.
[6] D.E. Morgan, Dual-energy CT of the abdomen, Abdom. Imaging 39 (February
(1))  (2014) 108–134, http://dx.doi.org/10.1007/s00261-013-0033-5.
[7]  L.J. Zhang, J. Peng, S.Y. Wu,  et al., Liver virtual non-enhanced CT with
dual-source, dual-energy CT: a preliminary study, Eur. Radiol. 20 (2010)
2257–2264.
[8] T.S. Cook, S.L. Zimmerman, S.R. Steingall, W.W.  Boonn, W.J. Kim, An algorithm
for  intelligent sorting of CT-related dose parameters, Digit Imag. 25 (February
(1)) (2012) 179–188, http://dx.doi.org/10.1007/s10278-011-9410-1.
PMID:2179649.
[9] T. Henzler, C. Fink, S.O. Schoenberg, U.J. Schoepf, Dual-energy CT: radiation
dose aspects, AJR Am. J. Roentgenol. 199 (November (5 Suppl)) (2012)
S16–S25, http://dx.doi.org/10.2214/AJR.12.9210, Review: Erratum in: AJR Am.
J.  Roentgenol., 2013, 200 March (3), 705, PMID: 23097163.
10] B.M. Yeh, J.A. Shepherd, Z.J. Wang, H.S. Teh, R.P. Hartman, S. Prevrhal,
Dual-energy and low-kVp CT in the abdomen, AJR Am. J. Roentgenol. 193
(2009) 47–54, PMID: 19542394.
11] A. Graser, T.R. Johnson, H. Chandarana, M.  Macari, Dual energy CT:
preliminary observations and potential clinical applications in the abdomen,
Eur. Radiol. 19 (2009) 13–23, PMID: 18677487.
12] H.A. Edmonson, P.E. Steiner, Primary carcinoma of the liver, Cancer 7 (1954)
462–503.
13] K.A. Mc Glynn, W.T. London, Epidemiology and natural history of
hepatocellular carcinoma, Best Pract. Res. Clin. Gastroenterol. 19 (2005) 3–23,
PMID: 15757802.
14] R.P. Beasley, L.Y. Hwang, C.C. Lin, C.S. Chien, Hepatocellular carcinoma and
hepatitis B virus. A prospective study of 22707 men  in Taiwan, Lancet 2
(1981) 1129–1133, PMID: 6118576.
15] C.A. Coursey, R.C. Nelson, D.T. Boll, E.K. Paulson, L.M. Ho, A.M. Neville, D.
Marin, R.T. Gupta, Dual-energy multidetector CT: how does it work, what can
it  tell us, and when can we  use it in abdominopelvic imaging? Radiographics
30  (July–August (4)) (2010) 1037–1055, PMID: 20631367.
16] H. Tsukuma, T. Hiyama, S. Tanaka, et al., Risk factors for hepatocellular
carcinoma among patients with chronic liver disease, N. Engl. J. Med. 328
(1995) 1797–1801.
17] G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, P. Almasio, F.
Nevens, et al., Morbidity and mortality in compensated cirrhosis type C: a
retrospective follow-up study of 384 patients, Gastroenterology 112 (1997)
463–472, PMID: 9024300.
18] C. Niederau, S. Lange, T. Heintges, A. Erhardt, M.  Buschkamp, D. Hurter, M.
Nawrocki, et al., Prognosis of chronic hepatitis C: results of a large,
prospective cohort study, Hepatology 8 (1998) 1687–1695, PMID: 9828236.
19] J.A. Marrero, R.J. Fontana, A. Barrat, F. Askari, H.S. Conjeevaram, G.L. Su, A.S.
Lok,  Prognosis of hepatocellular carcinoma: comparison of 7 staging systems
in  an American cohort, Hepatology 41 (2005) 707–716, PMID: 15795889.
20] F. Trevisani, P.E. D’Intino, A.M. Morselli-Labate, G. Mazzella, E. Accogli, P.
Caraceni, M. Domenicali, et al., Serum alpha-fetoprotein for diagnosis of
hepatocellular carcinoma in patients with chronic liver disease: inﬂuence of
HBsAg and anti-HCV status, J. Hepatol. 34 (2001) 570–575, PMID: 11394657.
21] M.  Hayashi, O. Matsui, K. Ueda, Y. Kawamori, T. Gabata, M. Kadoya,
Progression to hypervascular hepatocellular carcinoma: correlation with
intranodular blood supply evaluated with CT during intraarterial injection of
al of R
[
[
[
[
[
[
[
[
[
[
(12)) (2010) 2870–2875.
[32] S.H. Lee, J. Hur, Y.J. Kim, H.J. Lee, Y.J. Hong, Choi Additional value ofS.T. Laroia et al. / European Journ
contrast material, Radiology 225 (October (1)) (2002) 143–149 (PMID:
12354998.
22] O. Matsui, Imaging of multistep human hepatocarcinogenesis by CT during
intra-arterial contrast injection, Intervirology 47 (3–5) (2004) 271–276,
PMID: 15383735.
23] M.  Sherman, Screening for hepatocellular carcinoma, Baillieres Best Pract.
Res. Clin. Gastroenterol. 13 (1999) 623–635, PMID: 10654924.
24] G. Fattovich, T. Stroffolini, I. Zagni, F. Donato, Hepatocellular carcinoma in
cirrhosis: incidence and risk factors, Gastroenterology 127 (November (5
Suppl. 1)) (2004) S35–S50, PMID: 15508101.
25] E. Robinson, J. Babb, H. Chandarana, M.  Macari, Dual source dual energy
MDCT: comparison of 80 kVp and weighted average 120 kVp data for
conspicuity of hypo-vascular liver metastases, Invest. Radiol. 45 (2010)
413–418, PMID: 20458250.
26] K.S. Kim, J.M. Lee, S.H. Kim, et al., Image fusion in dual energy computed
tomography for detection of hypervascular liver hepatocellular carcinoma:
phantom and preliminary studies, Invest. Radiol. 45 (2010) 149–157, PMID:
20142749.
27] T.R. Johnson, B. Krauss, M.  Sedlmair, et al., Material differentiation by dual
energy CT: initial experience, Eur. Radiol. 17 (2007) 1510–1517, PMID:
17151859.adiology Open 3 (2016) 162–171 171
28] D. Marin, R.C. Nelson, E. Samei, et al., Hypervascular liver tumors: low tube
voltage, high tube current multidetector CT during late hepatic arterial phase
for detection–initial clinical experience, Radiology 251 (2009) 771–779,
PMID: 19346514.
29] J.G. Fletcher, N. Takahashi, R. Hartman, et al., Dual-energy and dual-source CT:
is  there a role in the abdomen and pelvis? Radiol. Clin. North Am. 47 (2009)
41–57, PMID: 19195533.
30] D. Marin, R.C. Nelson, S.T. Schindera, et al., Low-tube-voltage,
high-tube-current multidetector abdominal CT: improved image quality and
decreased radiation dose with adaptive statistical iterative reconstruction
algorithm-initial clinical experience, Radiology 254 (2010) 145–153, PMID:
20032149.
31] C.N. De Cecco, V. Buffa, S. Fedeli, et al., Dual energy CT (DECT) of the liver:
conventional versus virtual unenhanced images, Eur. Radiol. 20 (Decemberdual-energy CT to differentiate between benign and malignant mediastinal
tumors: an initial experience, Eur. J. Radiol. 82 (November (11)) (2013)
2043–2049, http://dx.doi.org/10.1016/j.ejrad.2013.05.040, Epub 2013 Jun 29.
